PADI2

Across TCGA pan-cancer cohorts, PADI2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PADI2 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PADI2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PADI2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and OV are the cancer types where PADI2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.201	0.769	<.001	48	view →
UCEC	DFS	Median	All	0.968	0.617	.007	20	view →
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	15	view →
COAD	DFS	Median	All	0.224	0.700	.002	12	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
SCLC	OS	Median	All	0.274	0.711	.008	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PADI2–HNSC (OS)

Open the HNSC breakdown →